TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19382890

Group type: EXPERIMENTAL
Intervention: Estradiol valerate (E2V)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: 17beta‐estradiol
Number of subjects: 192

Group type: COMPARATOR
Intervention: Epimedium pubescens decoction
Number of subjects: 192
Study: 17699476

Group type: EXPERIMENTAL
Intervention: C.E.R.A. once monthly
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: C.E.R.A. twice monthly
Number of subjects: 572

Group type: COMPARATOR
Intervention: Epoetin
Number of subjects: 572
Study: 15073671

Group type: EXPERIMENTAL
Intervention: Full-dose ganciclovir (5 mg/kg intravenously [iv] twice daily)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Half-dose ganciclovir (5 mg/kg iv once daily) plus half-dose foscarnet (90 mg/kg iv once daily)
Number of subjects: 48
Study: 12083045

Group type: EXPERIMENTAL
Intervention: Intestinal cleansers
Number of subjects: 90

Group type: COMPARATOR
Intervention: No intestinal cleansers (Control)
Number of subjects: 90
Study: 9669786

Group type: EXPERIMENTAL
Intervention: Intensive treatment (n = 586)
Number of subjects: 1168

Group type: COMPARATOR
Intervention: Conventional treatment (n = 582)
Number of subjects: 1168
Study: 7915090

Group type: EXPERIMENTAL
Intervention: Pancuronium 0.08 mg/kg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Vecuronium 0.08 mg/kg
Number of subjects: 30
Study: 3242978

Group type: EXPERIMENTAL
Intervention: Histamine
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Prostaglandin D2 (PGD2)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 9 alpha,11 beta-PGF2
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Combination of histamine and PGD2
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 8
Study: 29861026

Group type: EXPERIMENTAL
Intervention: Mindfulness meditation group (six weeks of mindfulness meditation, four to five times per week)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Mindfulness meditation group (female meditators)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (matched experiential activity with no meditation component)
Number of subjects: 100
Study: 29261503

Group type: EXPERIMENTAL
Intervention: Training package including contraceptive technology update and interventions to improve counseling and clinical skills and business practices
Number of subjects: 965

Group type: EXPERIMENTAL
Intervention: Training package
Number of subjects: 965

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 965
Study: 25369726

Group type: EXPERIMENTAL
Intervention: Oxybutynin
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Tolterodine
Number of subjects: 301

Group type: COMPARATOR
Intervention: Oxybutynin and Tolterodine
Number of subjects: 301
Study: 23168303

Group type: EXPERIMENTAL
Intervention: Child- and parent-focused developmental care (5 sessions)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Standard child-focused developmental care (5 sessions)
Number of subjects: 178
Study: 21681697

Group type: EXPERIMENTAL
Intervention: Intralesional 5-Fluorouracil combined with topical silicone
Number of subjects: 50

Group type: COMPARATOR
Intervention: Perilesional surgical excision of keloids combined with topical silicone
Number of subjects: 50
Study: 18505169

Group type: EXPERIMENTAL
Intervention: CD4+ T-cell count-guided use of ART (Drug Conservation arm; DC)
Number of subjects: 5472

Group type: COMPARATOR
Intervention: Continuous ART (Viral Suppression arm; VS)
Number of subjects: 5472
Study: 16783561

Group type: EXPERIMENTAL
Intervention: Clarithromycin 800 mg daily for 6 days
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Verapamil 240 mg daily for 6 days
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 14666027

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (100 mg/kg into cardiopulmonary bypass prime followed by infusion at 20 mg.kg(‐1).h(‐1), n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (n = 20)
Number of subjects: 40
Study: 10844878

Group type: EXPERIMENTAL
Intervention: Orthodox treatment (Version A)
Number of subjects: 398

Group type: COMPARATOR
Intervention: Unconventional treatment (Version B)
Number of subjects: 398
Study: 8857435

Group type: EXPERIMENTAL
Intervention: Transgastric, pulsed Doppler echocardiography
Number of subjects: 30

Group type: COMPARATOR
Intervention: Thermodilution (TD)
Number of subjects: 30
Study: 1739873

Group type: EXPERIMENTAL
Intervention: Calcitonin (50 U on alternate days for 2 weeks monthly) + Calcium (500 mg/day)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Calcitonin (50 U on alternate days for 2 weeks monthly) + Calcium (500 mg/day) + Phosphate (750 mg/day)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Calcitonin (50 U on alternate days for 2 weeks monthly) + Calcium (500 mg/day) + Norandrostenolone decanoate (50 mg/month)
Number of subjects: 45
Study: 6149531

Group type: EXPERIMENTAL
Intervention: Almitrine bismesylate
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 31362736

Group type: EXPERIMENTAL
Intervention: Dispensing practices for anti-malarials
Number of subjects: 230

Group type: COMPARATOR
Intervention: Experience of dispensers
Number of subjects: 230
Study: 29869556

Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ibrutinib
Number of subjects: 0
Study: 27089235

Group type: EXPERIMENTAL
Intervention: Culturally sensitive relationship education program
Number of subjects: 20

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 20
Study: 24750172

Group type: EXPERIMENTAL
Intervention: Teenage pregnancy prevention program
Number of subjects: 816
Study: 23137504

Group type: COMPARATOR
Intervention: Simultaneous CRT
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Optimized CRT
Number of subjects: 238
Study: 19304567

Group type: EXPERIMENTAL
Intervention: hylan G-F 20
Number of subjects: 253

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 253
Study: 18565275

Group type: EXPERIMENTAL
Intervention: l-tetrahydropalmatine (l-THP)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 15377573

Group type: EXPERIMENTAL
Intervention: Routine physiotherapy
Number of subjects: 286

Group type: COMPARATOR
Intervention: Advice on remaining active from a physiotherapist
Number of subjects: 286
Study: 11686540

Group type: EXPERIMENTAL
Intervention: First-degree relatives of individuals with Type 2 diabetes
Number of subjects: 235

Group type: COMPARATOR
Intervention: Non-relatives
Number of subjects: 235
Study: 9672449

Group type: COMPARATOR
Intervention: Plain lidocaine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Warmed lidocaine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Buffered lidocaine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Warmed, buffered lidocaine
Number of subjects: 20
Study: 7544041

Group type: EXPERIMENTAL
Intervention: Teflon-coated catheters
Number of subjects: 0

Group type: COMPARATOR
Intervention: Latex-coated catheters
Number of subjects: 0

Group type: COMPARATOR
Intervention: Silicone-coated catheters
Number of subjects: 0
Study: 2686340

Group type: EXPERIMENTAL
Intervention: Enisoprost (prostaglandin E1 analogue) at doses of 10, 25, 50, 100, 200, or 400 micrograms
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 792865

Group type: EXPERIMENTAL
Intervention: Diflucortolone valerate (ointment)
Number of subjects: 27
Study: 29083225

Group type: EXPERIMENTAL
Intervention: Bodily movement
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Tipping
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control (untreated group)
Number of subjects: 43
Study: 27219235

Group type: EXPERIMENTAL
Intervention: Percutaneous Aponeurotomy and Lipofilling (PALF)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Limited Fasciectomy
Number of subjects: 80
Study: 24674235

Group type: EXPERIMENTAL
Intervention: Full voucher-based CM intervention
Number of subjects: 131

Group type: COMPARATOR
Intervention: Lite voucher-based CM intervention
Number of subjects: 131
Study: 22253016

Group type: EXPERIMENTAL
Intervention: Oral-sparing group (OR-SP), n = 24
Number of subjects: 48

Group type: COMPARATOR
Intervention: Oral-unsparing group (OR-USP), n = 24
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Oral-sparing group (OR-SP)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Oral-unsparing group (OR-USP)
Number of subjects: 48
Study: 20551644

Group type: EXPERIMENTAL
Intervention: FeSO(4) gel (1 mmol/l FeSO(4))
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: F gel (NaF 1.23%)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo gel (negative control)
Number of subjects: 10
Study: 18792100

Group type: EXPERIMENTAL
Intervention: HPV test at rlu ratio cutoff 1.00
Number of subjects: 18438

Group type: EXPERIMENTAL
Intervention: HPV test at rlu ratio cutoff 3.00
Number of subjects: 18438

Group type: EXPERIMENTAL
Intervention: HPV test at rlu ratio cutoff 10.00
Number of subjects: 18438

Group type: COMPARATOR
Intervention: Conventional cytology
Number of subjects: 18438
Study: 16180954

Group type: EXPERIMENTAL
Intervention: Physical practice
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Mental practice
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control
Number of subjects: 24
Study: 12520146

Group type: EXPERIMENTAL
Intervention: Cutting balloon (n=30)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Stenting alone (n=31)
Number of subjects: 61
Study: 10978853

Group type: EXPERIMENTAL
Intervention: HMB supplementation (3.0 g HMB/d)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 8791019

Group type: EXPERIMENTAL
Intervention: Bromocriptine monotherapy
Number of subjects: 59

Group type: COMPARATOR
Intervention: Bromocriptine combined with levodopa
Number of subjects: 59
Study: 1636394

Group type: EXPERIMENTAL
Intervention: 2% sodium cromoglycate eyedrops
Number of subjects: 68

Group type: COMPARATOR
Intervention: terfenadine
Number of subjects: 68
Study: 6148005

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 333

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Overall study (nonblack patients)
Number of subjects: 333
Study: 30716550

Group type: EXPERIMENTAL
Intervention: EHS plus ABC (Attachment and Biobehavioral Catch-up)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Control group (home-based EHS plus 10 weekly books)
Number of subjects: 153
Study: 30121640

Group type: EXPERIMENTAL
Intervention: 5-FU bolus
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: 5-FU continuous infusion
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control group (no 5-FU)
Number of subjects: 132
Study: 26830380

Group type: EXPERIMENTAL
Intervention: Planned cesarean delivery
Number of subjects: 4603

Group type: COMPARATOR
Intervention: Planned vaginal delivery
Number of subjects: 4603
Study: 24780501

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: CER-001 3 mg/kg
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: CER-001 6 mg/kg
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: CER-001 12 mg/kg
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: Major cardiovascular events
Number of subjects: 507
Study: 22836250

Group type: EXPERIMENTAL
Intervention: Hydrocortisone and Yohimbine (combined administration)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydrocortisone alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Yohimbine alone
Number of subjects: 0
Study: 20308693

Group type: EXPERIMENTAL
Intervention: Caffeine (4.5 mg/kg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 17902094

Group type: EXPERIMENTAL
Intervention: High oral carbohydrate (CHO) beverage (125 mg/ml)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Low oral carbohydrate (CHO) beverage (25 mg/ml)
Number of subjects: 12
Study: 16096241

Group type: EXPERIMENTAL
Intervention: Vocational training programme plus psychosomatic treatment
Number of subjects: 266

Group type: COMPARATOR
Intervention: Treatment-as-usual (control)
Number of subjects: 266
Study: 11911556

Group type: EXPERIMENTAL
Intervention: Sprinkle-dose regimen of 60-mg MSER capsule on applesauce
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intact 60-mg MSER capsule swallowed whole
Number of subjects: 30
Study: 10382080

Group type: EXPERIMENTAL
Intervention: Intrauterine delivery system releasing progesterone (IDS-P)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No IDS-P (control)
Number of subjects: 0
Study: 7697274

Group type: EXPERIMENTAL
Intervention: Allergen immunotherapy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Mite immunotherapy
Number of subjects: 20
Study: 3606850

Group type: EXPERIMENTAL
Intervention: Needle aspiration alone
Number of subjects: 62

Group type: COMPARATOR
Intervention: Incision and drainage
Number of subjects: 62
Study: 29945905

Group type: EXPERIMENTAL
Intervention: NIV-Physical training
Number of subjects: 47

Group type: COMPARATOR
Intervention: Physical training alone
Number of subjects: 47
Study: 26612407

Group type: EXPERIMENTAL
Intervention: EAS regimen (esomeprazole 20 mg b.i.d., amoxicillin 500 mg q.i.d., sitafloxacin 100 mg b.i.d.)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: EMS regimen (esomeprazole 20 mg b.i.d., metronidazole 250 mg b.i.d., sitafloxacin 100 mg b.i.d.)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Both EAS and EMS regimens
Number of subjects: 80
Study: 24402559

Group type: EXPERIMENTAL
Intervention: Vorapaxar
Number of subjects: 249

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 249
Study: 23550916

Group type: EXPERIMENTAL
Intervention: Brinzolamide/timolol FC
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Brimonidine/timolol FC
Number of subjects: 50

Group type: COMPARATOR
Intervention: Both adjunctive FC therapies
Number of subjects: 50
Study: 20584056

Group type: EXPERIMENTAL
Intervention: Aortic valve replacement (AVR)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (17 subjects without known cardiac disease)
Number of subjects: 27
Study: 18412989

Group type: EXPERIMENTAL
Intervention: Markers of bone turnover (e.g., serum bone alkaline phosphatase, total osteocalcin, procollagen type I N-terminal propeptide)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antiresorptive therapy (e.g., hormone-replacement therapy, raloxifene, bisphosphonates)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nutritional interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bone turnover markers
Number of subjects: 0
Study: 20064989

Group type: EXPERIMENTAL
Intervention: Sodium dichloroisocyanurate (NaDCC) tablets
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 240
Study: 16263979

Group type: EXPERIMENTAL
Intervention: Sublingual sugar administration (SG) - 2.5 g of sugar under the tongue, with subgroups of 0.1 g/kg, 0.15 g/kg, and 0.2 g/kg
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Intravenous dextrose administration (IG) - 8 mL of 30% dextrose in a single bolus
Number of subjects: 69

Group type: COMPARATOR
Intervention: Oral sugar administration (OG) - 2.5 g of sugar
Number of subjects: 69

Group type: COMPARATOR
Intervention: Water administration (C)
Number of subjects: 69
Study: 11187414

Group type: EXPERIMENTAL
Intervention: Weight loss intervention (group meetings and individual counseling focused on dietary change, physical activity, and social support)
Number of subjects: 1191

Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 1191

Group type: EXPERIMENTAL
Intervention: Weight loss intervention
Number of subjects: 1191

Group type: EXPERIMENTAL
Intervention: Weight loss intervention (subgroup analysis)
Number of subjects: 1191
Study: 9536540

Group type: EXPERIMENTAL
Intervention: 2% fusidic acid lotion (Fucidin lotion)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 52
Study: 7906472

Group type: EXPERIMENTAL
Intervention: Topical 0.5% timolol
Number of subjects: 57
Study: 3300313

Group type: EXPERIMENTAL
Intervention: Norfloxacin (400 mg orally twice daily)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Trimethoprim/sulfamethoxazole
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Norfloxacin
Number of subjects: 104
Study: 11837758

Group type: EXPERIMENTAL
Intervention: High dose glucocorticoid pulse therapy (GPT)
Number of subjects: 102

Group type: COMPARATOR
Intervention: No glucocorticoid pulse therapy (Control)
Number of subjects: 102
Study: 31481504

Group type: EXPERIMENTAL
Intervention: Rituximab (R) at 375 mg/m2 weekly for 4 weeks and Ipilimumab (I) at 3 mg/kg on day 1 and every 3 weeks for four doses
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Rituximab (R) with Ipilimumab (I)
Number of subjects: 33

Group type: COMPARATOR
Intervention: R with I delayed 2 weeks
Number of subjects: 33
Study: 29172945

Group type: EXPERIMENTAL
Intervention: Investigational acellular pertussis vaccines (aP) containing pertussis antigens PT, FHA, and PRN at different dosages
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Investigational TdaP vaccines (containing TT and DT)
Number of subjects: 420

Group type: COMPARATOR
Intervention: Licensed TdaP comparator containing chemically inactivated PT
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: All investigational study formulations
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Investigational aP4 group
Number of subjects: 420
Study: 27329896

Group type: EXPERIMENTAL
Intervention: Parallel fiber post group
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Double taper fiber post group
Number of subjects: 53

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 53
Study: 25455692

Group type: EXPERIMENTAL
Intervention: Rotigotine (up to 16 mg/24 h)
Number of subjects: 420

Group type: COMPARATOR
Intervention: Ropinirole (up to 15 mg/day)
Number of subjects: 420

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Rotigotine
Number of subjects: 420

Group type: COMPARATOR
Intervention: Ropinirole
Number of subjects: 420
Study: 21950653

Group type: COMPARATOR
Intervention: CONTROLS
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: RELATIVES
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: IGT
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: DMA
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: DMB
Number of subjects: 55
Study: 20092848

Group type: EXPERIMENTAL
Intervention: Intraoperative fragment retrieval (group 1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Exhaustive lithotripsy and spontaneous fragment expulsion (group 2)
Number of subjects: 60
Study: 17391350

Group type: EXPERIMENTAL
Intervention: Mood episode or symptoms, borderline/antisocial personality disorder, male gender, living alone, hypnotic drug, drugs for physical illness
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Hypomanic symptoms
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Hypomanic symptoms in patients not in acute bipolar episode
Number of subjects: 253
Study: 15483105

Group type: EXPERIMENTAL
Intervention: Metformin (850 mg/d) added to Flutamide (62.5 mg/d) and ethinylestradiol-drospirenone for 3 months in study A.
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Continuation of Metformin after 17 months of therapy in study B.
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group in study A (no Metformin).
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group in study B (discontinuation of Metformin).
Number of subjects: 73
Study: 12429319

Group type: EXPERIMENTAL
Intervention: 5F urethral catheters
Number of subjects: 31

Group type: COMPARATOR
Intervention: 10F urethral catheters
Number of subjects: 31
Study: 10651170

Group type: EXPERIMENTAL
Intervention: CHF patients with DVI during low-workload exercise
Number of subjects: 22

Group type: COMPARATOR
Intervention: CHF patients without DVI during low-workload exercise
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: CHF patients with DVI during peak exercise
Number of subjects: 22

Group type: COMPARATOR
Intervention: CHF patients without DVI during peak exercise
Number of subjects: 22
Study: 7666090

Group type: EXPERIMENTAL
Intervention: Interferon gamma (IFN‐gamma) 0.2 mg total dose by subcutaneous injection daily for 6 months
Number of subjects: 99

Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Interferon gamma (IFN‐gamma)
Number of subjects: 99
Study: 2669980

Group type: EXPERIMENTAL
Intervention: GHB (50 mg GHB/kg/night given 25 mg/kg h.s. and 25 mg/kg 3 hr later)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: GHB
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 1100303

Group type: EXPERIMENTAL
Intervention: Melengestrol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dexamethasone
Number of subjects: 0
Study: 31812934

Group type: EXPERIMENTAL
Intervention: Early and systematic integration of palliative care (PC) into oncological care
Number of subjects: 186

Group type: COMPARATOR
Intervention: Standard oncological care alone
Number of subjects: 186
Study: 31437272

Group type: EXPERIMENTAL
Intervention: Community-based self-care promoting program
Number of subjects: 457

Group type: COMPARATOR
Intervention: Placebo social calls (Control)
Number of subjects: 457
Study: 28590833

Group type: EXPERIMENTAL
Intervention: Decision Aid (DA)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 79
Study: 26041862

Group type: EXPERIMENTAL
Intervention: CHK-Alpha (CHKA) immunohistochemistry (IHC)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Normal prostate tissue
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Ki67 labelling index (LI) in malignant prostate cores
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: CHK intensity stratification
Number of subjects: 125
Study: 23747140

Group type: EXPERIMENTAL
Intervention: Older female fallers
Number of subjects: 61

Group type: COMPARATOR
Intervention: Older female non-fallers
Number of subjects: 61

Group type: COMPARATOR
Intervention: Younger females
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Older female fallers and non-fallers
Number of subjects: 61
Study: 22048097

Group type: EXPERIMENTAL
Intervention: Three-dimensional CT
Number of subjects: 85

Group type: COMPARATOR
Intervention: Two-dimensional CT
Number of subjects: 85